



Agency for Healthcare Research and Quality

Advancing Excellence in Health Care • www.ahrq.gov

Panel 5: Evaluation Perspective

**Implementation of Risk Minimization
Action Plans to Support Quality Use
of Pharmaceuticals; Opportunities
and Challenges:**

A Public Workshop

June 25 and 26, 2007

Evaluation

- Main purpose: To ensure whether the risk minimization program is achieving the desired goal or objective.
- Other purposes

Panelists

- **Anne Trontell, M.D., M.P.H.**
 - Agency of Health Care Research and Quality
- **Nancy Allen Lapointe, Pharm.D.**
 - Duke University
- **Brian Strom, M.D., M.P.H.**
 - University of Pennsylvania
- **Judith A Racoosin, M.D., M.P.H.**
 - Food and Drug Administration

Ground Rules

- Each panelist will present for ~15 minutes
- Questions and comments should be made at the end of session.
- Need to come to Mics.
- Please identify yourself and the Panelist to whom the question is addressed.

